

## **ELI LILLY AND COMPANY – CITATIONS**

In this section you will find citations to select publications regarding investigational assets and investigational uses for approved products that may be of interest to our investors. For a more complete listing of Lilly sponsored clinical trials and available study results, please visit the [ClinicalTrials.gov](https://ClinicalTrials.gov) website.

## Biomedicines

### **BACE Inhibitor (AZD3293/LY3314814) – Alzheimer’s Disease**

- Eketjäll S, Janson J, Kaspersson K, Bogstedt A, Jeppsson F, Fälting J, Haerberlein SB, Kugler AR, Alexander RC, Cebers G. AZD3293: A novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics. *Journal of Alzheimer's Disease.* 2016;50(4):1109-1123.

### **Baricitinib (LY3009104) – Rheumatoid Arthritis**

- Genovese M, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie S, Koch A, Cardillo T, de Bono S, Rooney T, Macias W, Schlichting D, Smolen J. Baricitinib in Patients with Refractory Rheumatoid Arthritis. *New England Journal of Medicine.* 2016;374(13):1243-1252.
- Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. *New England Journal of Medicine.* 2017;376(7):652-662.
- Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CA, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T. Baricitinib, Methotrexate, or Combination in Patients with Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment. *Arthritis Rheumatology.* 2016;69(3):506-517.
- Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. *Annals of the Rheumatic Diseases.* 2017;76(1):88-95.

### **Galcanezumab (LY2951742) – Migraine Prevention**

- Dodick D, Goadsby P, Pierings E, Scherer J, Sweeney S, Grayzel D. CGRP Monoclonal Antibody LY2951742 for the Prevention of Migraine: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study. *Lancet Neurology.* 2014;13(9):885-92.
- Oakes TM, Zhang Q, Ferguson MB, Skljarevski V, Martinez JM, Johnson KW, Schacht AL, Due MR, Goadsby PJ, Dodick DW. Efficacy and safety of LY2951742 in a randomized, double-blind, placebo-controlled, dose-ranging study in patients with migraine. American Headache Society - 58th Annual Scientific Meeting. 2016;56(S1):68.

- Detke H, Skljarevski, Yang J, Ahl J, Wang S, Millen B, Aurora S. A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study. Presented at American Headache Society - 59th Annual Scientific Meeting. June 8, 2017, Boston MA.
- Stauffer V, Zhang Q, Skljarevski V, Millen B, Yang J, Selzler K, Conley R. Phase 3 Study (EVOLVE-1) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase. Presented at American Headache Society - 59th Annual Scientific Meeting. June 8, 2017, Boston MA.
- Skljarevski V, Zhang Q, Detke H, Millen B, Yang J, Selzler K, Conley R. Phase 3 Study (EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase. Presented at American Headache Society - 59th Annual Scientific Meeting. June 8, 2017, Boston MA.

#### **Ixekizumab (LY2439821) – Psoriatic Arthritis**

- Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David Henry Adams, Lisa Kerr, Chin Lee, Catherine Shuler, Mark Genovese. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase III trial. *Lancet.* 2017;389(10086):2317-2327.
- Désirée van der Heijde, Masato Okada, Chin Lee, Catherine Shuler, Suchitrita Rathmann, Chen-Yen Lin, Philip Mease. Radiographic progression of structural joint damage in patients with active psoriatic arthritis treated with ixekizumab over 52 weeks. *Annals of the Rheumatic Diseases.* 2017;76(supplement 2):144.
- Laura Coates, Philip Mease, Elaine Husni, Eric Lespessailles, David Henry Adams, Olivier Benichou, Lisa Kerr, Philip Helliwell. Ixekizumab Reduces Disease Activity in Active Psoriatic Arthritis Patients Who Had Previous Inadequate Response to Tumour Necrosis Factor-Inhibitors. *Annals of the Rheumatic Diseases.* 2017;76(supplement 2):679.
- Arthur Kavanaugh, Ronald Vender, Julie Birt, David Henry Adams, Olivier Benichou, Chen-Yen Lin, Peter Nash. Ixekizumab Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumour Necrosis Factor-Inhibitors. *Annals of the Rheumatic Diseases.* 2017;76(supplement 2):941.
- Vibeke Strand, Alice Gottlieb, Tore Kvien, April Naegeli, Chen-Yen Lin, Olivier Benichou, Julie Birt. Efficacy of Ixekizumab Improving SF-36 Scores in Biologic DMard-Niave Patients with Active Psoriatic Arthritis: Results from a Phase 3 Study (SPIRIT-P1). *Annals of the Rheumatic Diseases.* 2017;76(supplement 2):1334.

### Lasmiditan (LY2951742)- Acute Migraine

- Färkkilä M, Diener HC, Géraud G, Láinez M, Schoenen J, Harner N, Pilgrim A, Reuter U; COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT<sub>1F</sub> receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. *Lancet Neurol.* 2012;11(5):405-13.
- Ferrari MD, Färkkilä M, Reuter U, Pilgrim A, Davis C, Krauss M, Diener HC; European COL-144 Investigators. Acute treatment of migraine with the selective 5-HT<sub>1F</sub> receptor agonist lasmiditan - a randomised proof-of-concept trial. *Cephalalgia.* 2010;30(10):1170-8.
- Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, Xu YC. Preclinical pharmacological profile of the selective 5-HT<sub>1F</sub> receptor agonist lasmiditan. *Cephalalgia.* 2010;30(10):1159-69.
- Kuca B, Berg P, Wietecha L, Aurora S. Lasmiditan (200 mg and 100 mg) Compared to Placebo for Acute Treatment of Migraine. Presented at American Headache Society - 59th Annual Scientific Meeting. June 8, 2017, Boston MA.

### Solanezumab (LY2062430) – Alzheimer's Disease

- Doody RS, Thomas RG, Siemers E, Lui-Seifert H, Mohs R, for the Solanezumab Study Group, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, and Aisen PS for the Alzheimer's Disease Cooperative Study Steering Committee. Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. *New England Journal of Medicine.* 2014;370(4):311-21.
- Siemers E, Sundell K, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo M, Dean RA, DeMattos R. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. *Alzheimer's & Dementia.* 2016;12(2):110-120.
- Liu-Seifert H, Siemers E, Holdridge K, Andersen S, Lipkovich I, Carlson C, Sethuraman G, Hoog S, Hayduk R, Doody R, Aisen P. Delayed-start analysis: mild Alzheimer patients in solanezumab trials, 3.5 years. *Alzheimer's & Dementia.* 2015;1(2):111-21.
- Liu-Seifert H, Siemers E, Price K, Han B, Selzler K, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease Dementia. *Journal of Alzheimer's Disease.* 2015;47(1):205-14.
- Siemers E, Holdridge K, Sundell K, Liu-Seifert H. Function and clinical meaningfulness of treatments for mild Alzheimer's disease. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring.* *Alzheimer's & Dementia.* 2016;2:105-112.

## Tanezumab – Cancer Pain, Chronic Low Back Pain, Osteoarthritis

- Sopata M, Katz N, Carey W, Smith MD, Keller D, Verburg KM, West CR, Wolfram G, Brown MT. Efficacy and Safety of Tanezumab in the Treatment of Pain from Bone Metastases. *Pain*. 2015;156(9):1703-1713.
- Kivitz AJ, Gimbel JS, Bramson C, Nemeth MA, Keller DS, Brown MT, West CR, Verburg KM. Efficacy and Safety of Tanezumab versus Naproxen in the Treatment of Chronic Low Back Pain. *Pain*. 2013;154(7):1009-21.
- Lane N, Schnitzer T, Birbara C, Mokhtarani M, Shelton D, Smith M, Brown M. Tanezumab for Treatment of Knee Osteoarthritis Pain. *New England Journal of Medicine*. 2010;363(15):1521-1531.
- Brown MT, Herrmann DN, Goldstein M, Burr AM, Smith MD, West CR, Verburg KM, Dyck PJ. Nerve Safety of Tanezumab, a Nerve Growth Factor Inhibitor for Pain Treatment. *Journal of Neurological Sciences*. 2014;345:139-47.
- Hochberg MC, Abramson SB, Vignon EP, Verburg KM, West CR, Smith MD, Tive L, Hungerford D. When is Osteonecrosis Not Osteonecrosis? Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. *Arthritis Rheumatology*. 2016;68:382-91.

## Tau PET Tracer

- Shcherbinin S, Schwarz AJ, Devous MD Sr., et al. Kinetics of the tau PET tracer [<sup>18</sup>F]-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment and Alzheimer's disease. *Journal of Nuclear Medicine*. 2016; 57(10): 1535-1542.
- Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al. Regional profiles of [<sup>18</sup>F]-AV-1451 tau PET images recapitulate key features of Braak histopathological stages. *Brain*. 2016; 139, 1539-1550.
- Pontecorvo MJ, Devous MD, Joshi AD, et al. Relationships between 18F-AV-1451 (aka 18F-T807) PET tau binding and amyloid burden in cognitively normal subjects and patients with cognitive impairments suspected of Alzheimer's disease. Presented at the meeting of the Society for Nuclear Medicine and Molecular Imaging, June 2015, Baltimore, MD.
- Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [<sup>18</sup>F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. *Alzheimer's & Dementia*. 2013; 9: 666-76.

- Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808. *Journal of Alzheimer's Disease*. 2014; 38:1, 171-84.

## Diabetes

### **Jardiance - Type 1 Diabetes Mellitus, Heart Failure**

- Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, Fagan NM, Kaspers S, Woerle HJ, Broedl UC, Johansen OE. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. *Diabetes Care*. 2014;37(5):1480-3. doi: 10.2337/dc13-2338
- Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, Woerle HJ, Broedl UC, Kaspers S. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). *Diabetes, Obesity and Metabolism*. 2015;17(10):928-35. doi: 10.1111/dom.12494
- Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. *European Heart Journal*. 2016;37(19):1526-34. doi: 10.1093/eurheartj/ehv728

### **Nasal Glucagon – Severe Hypoglycemia Rescue**

- Seaquist ER, Dulude H, Zhang MX, Rampakakis E, Rabasa-Lhoret R, Tsoukas GM, Conway JR, Weisnagel SJ, Gerety G, Woo V, Zhang S, Carballo D, Triest M, Piché CA, Guzman CB. Nasal Glucagon for the Treatment of Moderate-to-Severe Hypoglycemic Episodes in Real-World Settings in Adults with Type 1 Diabetes. Oral presentation at: American Diabetes Association; June 9, 2017; San Diego, CA.
- Deeb LC, Dulude H, Zhang MX, Zhang S, Reiner BJ, Piché CA, Guzman CB. Nasal Glucagon for the Treatment of Moderate to Severe Hypoglycemic Episodes in Children and Adolescents with Type 1 Diabetes in Home or School Settings. Poster presented at: International Society of Pediatric and Adolescent Diabetes; October 27, 2016; Valencia, Spain.
- Dulude H, Sicard E, Rufiange M, Sadoune AA, Carballo D, Triest M, Tafreshi M, Rampakakis E, Piché CA. Effects of Nasal Congestion from Common Cold on the PK and PD of Nasal Glucagon. Poster presented at: American Diabetes Association; June 10, 2016; New Orleans, LA.
- Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E,

Meng L, Beck RW. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: A randomized crossover non-inferiority study. *Diabetes Care.* 2016; 39(2):264-70. doi: 10.2337/dc15-1498

- Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio, LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Glucagon nasal powder: A promising alternative to intramuscular glucagon in youth with type 1 diabetes. *Diabetes Care.* 2016;39(4):555-562. doi: 10.2337/dc15-1606

#### **Ultra Rapid Insulin Lispro - Type 1&2 Diabetes Mellitus**

- Michael MD, Zhang C, Siesky AM, Cox AL, Sperry AE, Hansen RJ, Christe ME, Farmen MW, Wu H, Paavola CD, Moyers JS. Exploration of the Mechanism of Accelerated Absorption for a Novel Insulin Lispro Formulation. Poster presented at: American Diabetes Association; June 9, 2017; San Diego, CA.
- Pratt E, Leohr J, Heilmann C, Johnson J, Landschulz W. Treprostinil Causes Local Vasodilation, Is Well Tolerated, and Results in Faster Absorption of Insulin Lispro. Poster presented at: American Diabetes Association; June 9, 2017; San Diego, CA.
- Leohr J, Pratt EJ, Heilmann C, Johnson J, Kelly RP, Landschulz W. A Novel Insulin Lispro Formulation Containing Citrate and Treprostinil Demonstrates Faster Absorption and Onset of Insulin Action in Healthy Subjects. Poster presented at: American Diabetes Association; June 9, 2017; San Diego, CA.
- Kazda C, Leohr J, Liu R, Reddy S, Dellva MA, Lim ST, Loh MT, Knadler MP, Hardy T, Plum-Moerschel L. A Novel Formulation of Insulin Lispro Containing Citrate and Treprostinil Shows Faster Absorption and Improved Postprandial Glucose Excursions vs. Humalog in Patients with T1DM. Poster presented at: American Diabetes Association; June 9, 2017; San Diego, CA.
- Kapitza C, Leohr J, Liu R, Reddy S, Dellva MA, Matzopoulos M, Knadler MP, Loh MT, Hardy T, Kazda C. A Novel Formulation of Insulin Lispro Containing Citrate and Treprostinil Shows Significantly Faster Absorption and an Improvement in Postprandial Glucose Excursions vs. Humalog in Patients with T2DM. Poster presented at: American Diabetes Association; June 9, 2017; San Diego, CA.

#### **PCSK9 – CV Disease**

- Kastelein JJP, Nissen SE, Rader DJ, Hovingh GK, Wang MD, Shen T, Krueger KA. Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9

(PCSK9): a randomized, placebo controlled phase 2 study. *European Heart Journal*. 2016;137(17):1360-9]. doi:10.1093/eurheartj/ehv707

- Schroeder KM, Beyer TP, Hansen RJ, Han B, Pickard RT, Wroblewski VJ, Kowala MC1, Eacho PI. Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody. *Journal of Lipid Research*. 2015;56(11):2124-2132. doi: 10.1194/jlr.M061903
- Shen T, James DE, Krueger KA. Population pharmacokinetics (PK) and pharmacodynamics (PD) analysis of LY3015014, a monoclonal antibody to protein convertase subtilisin/kexin type 9 (PCSK9) in healthy subjects and hypercholesterolemia patients. *Pharmaceutical Research*. 2017;34(1):185-92. doi: 10.1007/s11095-016-2054-6.

## Oncology

### **Abemaciclib – Breast Cancer**

- Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. *J Clin Oncol*. 2017; June 3: doi: 10.1200/jco.2017.73.7585
- Maura N. Dickler, Sara Tolaney, Hope S. Rugo, Javier Cortés, Veronique Dieras, Debra A. Patt, Hans Wildiers, Clifford A. Hudis, Joyce A. O'Shaughnessy, Esther Zamora, Denise Yardley, Martin Frenzel, Andrew G. Koustenis and José Baselga. MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with HR+/HER2- breast cancer, after chemotherapy for metastatic disease *Clinical Cancer Research* 2017 DOI: 10.1158/1078-0432.CCR-17-0754
- Sonya C. Tate, Amanda K. Sykes, Palaniappan Kulanthaivel, Edward M. Chan, P. Kellie Turner, Damien M. Cronier. A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase 1 Clinical Trial in Cancer Patients. *Clinical Pharmacokinetics* (doi: 10.1007/s40262-017-0559-8)
- Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beerman M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. *Cancer Discovery*. 2016;6(7):740-53.



- Sara Hurvitz, Miguel Martin, María F. Abad, David Chan, Regan Rostorfer, Edgar Petru, Susana Barriga, Timothy M. Costigan, Charles W. Caldwell, Sameera Wijayawardana, Michael F. Press, and Dennis Slamon. Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with hormone receptor positive, HER2 negative breast cancer. San Antonio Breast Cancer Symposium; 2016 Dec; San Antonio, TX
- Muralidhar Beeram, Sara M. Tolaney, J. Thaddeus Beck, Maura N. Dickler, Alison K. Conlin, E. Claire Dees, Teresa L. Helsten, Paul R. Conkling, William J. Edenfield, Donald A. Richards, Siva Rama Prasad Kambhampati, Timothy Michael Costigan, Edward M. Chan, Shubham Pant, Kevin Kalinsky, Howard A. Burris, Carlos H. Becerra, Brent N. Rexer, Shannon L. Puhalla, Matthew P. Goetz. A Phase 1b Study of Abemaciclib, an inhibitor of CDK4 and CDK6, in Combination with Endocrine and HER2-targeted Therapies for Patients with Metastatic Breast Cancer. European Society for Medical Oncology 41st Congress; 2016 Oct 7-11; Copenhagen, Denmark.

#### Abemaciclib – Lung Cancer

- Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beerman M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. *Cancer Discovery.* 2016;6(7):740-53.
- Goldman JW, Shi P, Reck M, Paz-Ares L, Koustenis A, Hurt KC. Treatment rationale and study design for the JUNIPER study: A randomized phase 3 study of abemaciclib plus best supportive care versus erlotinib plus best supportive care in patients with stage IV non-small-cell lung cancer with a detectable KRAS mutation whose disease has progressed after platinum-based chemotherapy. *Clin Lung Cancer.* 2016;17(1):80-4.
- Goldman JW, Gandhi L, Patnaik A, Rosen LS, Hilton J, Papadopoulos KP, Tolaney SM, Beeram M, Raso DW, Beckmann RP, Kulanthaivel P, Frenzel M, Cronier D, Chan EM, Flaherty KT, Wen PY, Tolcher AW, Shapiro GI. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. American Society of Clinical Oncology; 2014; Chicago, IL.
- Karen Kelly, Jonathan W. Goldman, Pilar Garrido, Shadia Jalal, Daruka Mahadevan, Martin Gutierrez, Luis G. Paz-Ares, Mariano Provencio, Eric Schaefer, Monte Shaheen, Erica L. Johnston, Na Cai, William J. John, Edward S. Kim. LY2835219: Abemaciclib in combination with single agent options in stage IV NSCLC, a phase 1b study. World Conference on Lung Cancer; 2015; Denver, CO.

### Abemaciclib – Mechanistic Data

- Torres-Guzmán R, Calsina B, Hermoso A, Baquero C, Alvarez B, Amat J, McNulty AM, Gong X, Boehnke K, Du J, de Dios A, Beckmann R, Buchanan S, Lallena MJ. Preclinical Characterization of Abemaciclib in Hormone Receptor Positive Breast Cancer. *OncoTarget*. 2017. <http://dx.doi.org/10.18632/oncotarget.17778>
- LM Gelbert, S Cai, X Lin, C Sanchez-Martinez, M del Prado, MJ Lallena, R Torres, RT Ajamie, GN Wishart, RS Flack, B Neubauer, J Young, EM Chan, P Iversen, D Cronier, E Kreklau, A De Dios. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle dependent/independent anti-tumor activities alone/in combination with gemcitabine. *Invest New Drugs*. (2014); 32:825-837.

### Cyramza – 1<sup>st</sup> line gastric

I Chau, J Bendell, E Calvo, R Santana-Davila, HT Arkenau, G Mi, J Jin, J Rege, D Ferry, R Herbst, C Fuchs. Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. American Society of Clinical Oncology Annual Meeting (2017); Chicago, IL.

### Cyramza - 1st line lung

- K Nakagawa, E Garon, L Paz-Ares, S Ponce, J Corral, O Vidal, E Nadal, K Kiura, J Liu, S He, J Treat, R Dalal, P Lee, M Reck. Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in First-Line EGFR Mut + Stage IV NSCLC: Phase 1b Safety Results. 17<sup>th</sup> World Congress on Lung cancer (2016); Vienna, Austria.

### Cyramza - 2nd line liver

- A Zhu, J Park, B-Y Ryoo, C-J Yen, R Poon, D Pastorelli, J-F Blanc, H Chung, A Baron, T E F Pfiffer, T Okusaka, K Kubackova, J Trojan, J Sastre, I Chau, S-C Chang, P Abada, L Yang, J D Schwartz, M Kudo. Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma Following First-Line Therapy with Sorafenib: Results from the Randomized Phase III REACH Study. *Lancet Oncology*. 2015 July; 16(7):859-870. doi: 10.1016/S1470-2045(15)00050-9.

### Galunisertib - Cancer

- Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gaël Deplanque, Martin Fuchs, Joerg Trojan, Helmut Oettle, Mark Kozloff, Ann Cleverly, Ivelina Gueorguieva, Durisala Desaiyah, Michael Lahn, Al Blunt, Karim Benhadji, Joseph Taberner. A randomized phase 2, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine or

gemcitabine+placebo in patients with unresectable pancreatic cancer. AACR (2016) American Association for Cancer Research - 107th Annual Meeting. 2016; New Orleans, LA.

- Sandrine Faivre, Armando Santoro, Ed Gane, Robin K Kelley, Isabelle Ollivier Hourmand, Eric Assenat, Ivelina Gueorguieva, Ann Cleverly, Durisala Desai, Michael M Lahn, Eric Raymond, Karim A Benhadji, Gianluigi Giannelli. A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF- $\beta$ ) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP). ASCO (2016) American Society of Clinical Oncology - 52nd Annual Meeting. 2016; Chicago, IL.
- David Valcarcel, Amit Verma, Uwe Platzbecker, Valeria Santini, Aristoteles Giagounidis, Maria Diez- Campelo, Jan Janssen, Richard F Schlenk, Gianluca Gaidano, Jaime Perez de Oteyza, Ann L Cleverly, Alan Y Chiang, Michael M Lahn, Durisala Desai, Susan Guba. Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate Risk Patients with Myelodysplastic Syndromes. American Society of Hematology - 57th Annual Meeting. 2015; Orlando, FL.
- Alba A Brandes, Antoine Carpentier, Santosh Kesari, Juan Sepulveda, Helen Wheeler, Olivier Chinot, Lawrence Cher. LY2157299: A phase 2 randomized study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine monotherapy in recurrent glioblastoma. American Society of Clinical Oncology - 51st Annual Meeting. 2015; Chicago, IL.
- Waldschmidt, Mary Mulcahy, Charlotte Costentin, Beatriz Minguez, Pasqua P Papappicco, Ivelina Gueorguieva, Ann Cleverly. LY2157299: Evaluation of LY2157299 monohydrate, a TGF $\beta$  receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma: Phase 2 study results of safety, efficacy and PK/PD. European Association for the Study of the Liver - 49th Annual Meeting. 2014; London, UK.